Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug

Encouraging trial data is instilling both confidence and capital back into the psychedelic drug market, with estimates suggesting growth up towards $7 billion by the year 2032. One pharmaceutical company, Compass Pathways, has begun final stage studies aimed at using psilocybin for the treatment of patients with depression. CEO Kabir Nath joined Carol Massar and Alexis Christoforous on ‘Bloomberg Businessweek Daily’ to discuss commercial viability for psilocybin and the future of the psychedelic drug development market. (Source: Bloomberg)